Research progress on impact of gut microbiota on cancer immunotherapy upon immune-checkpoint blockers
10.3969/j.issn.1000-484X.2018.02.032
- VernacularTitle:肠道菌群影响免疫检查点抑制剂治疗癌症的研究进展
- Author:
Yun LI
1
;
Cheng ZHANG
;
Yu-Hang XU
;
Xiao-Yan LI
Author Information
1. 东北林业大学生命科学学院,哈尔滨150040
- Keywords:
Gut microbiota;
Cancer treatment;
Immune-checkpoint blockers(ICB);
Immune-related adverse events (irAEs);
Immune response
- From:
Chinese Journal of Immunology
2018;34(2):310-316
- CountryChina
- Language:Chinese
-
Abstract:
Numbers of commensal microbiota live in the human intestine.Intestinal flora can help their host digest food and their metabolite can affect human′s capacity of digestion.In addition,commensal microbiota can improve the ability of host against auto-immune disease and so on.Therefore,the commensal microbiota may be regarded as an essential"organ" in our body.Recent research has revealed that gut microbiota can affect the cancer immunotherapy upon immune-checkpoint blockers(ICB).Combined with recent study results,this article reviews the immune-related adverse events after cancer immunotherapy,introduction of gut microbiota and research progress on impact of gut microbiota on cancer immunotherapy upon immune-checkpoint blockers.In addition,there is an outlook for the future research on gut microbiota against cancer.This article will provide a theoretical reference for study of the relationship of gut microbiota and cancer treatment.
